Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 12, 2025

Chemoimmunotherapy for Patients with Resectable Non-Small Cell Lung Carcinoma: Real-World Data Analysis from a Surgical Point of View

View Full Paper
Ask AI
Bookmark
Share

Authors

NDNiels Michael Dörr-Jerat

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals surgical success and response patterns in patients with NSCLC, suggesting neoadjuvant CIT is feasible.

Key Points

  • Surgical resection after neoadjuvant chemoimmunotherapy showed a 56% stable disease rate in NSCLC patients.
  • Among patients receiving CIT, 61% achieved downstaging, highlighting the effectiveness of immune checkpoint inhibitors.
  • The median hospital stay was 9 days, with 28% of patients experiencing no surgical complications post-surgery.
  • The surgical approach included thoracotomy in 67% of cases, indicating diverse strategies for managing NSCLC.

Cite This Study

Niels Michael Dörr-Jerat (2025) studied this question.

synapsesocial.com/papers/68d41ed9713b0b5dfea67e1bhttps://doi.org/10.46889/jsrp.2025.6302
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real World Radiographic Response Rates and Preoperative Attrition in Patients With Nonsmall Cell Lung Cancer (NSCLC) Treated With Neoadjuvant Chemoimmunotherapy2025
  2. 2Efficacy of adjuvant therapy regimens administered during the perioperative period in resectable non-small cell lung cancer2025
  3. 3Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses2025
  4. 4A Real‐World Study of Resectable <scp>NSCLC</scp> Following Neoadjuvant Immunotherapy: Should Postoperative Adjuvant Immunotherapy be Recommended?2025 · 2 citations
  5. 5Clinical outcomes for neoadjuvant immunochemotherapy or chemotherapy versus concurrent chemoradiotherapy in limited-stage small-cell lung cancer: A retrospective, multi-center, real-world study.2025 · 1 citations